Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEP-HER2-DFO-89Zr
- Development stage
- Preclinical
- Lead developer
- Starpharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
DEP-HER2-DFO-89Zr (also known as DEP-HER2-zirconium) is a preclinical-stage, human epidermal growth factor receptor 2 (HER2)-targeted radiodiagnostic agent developed by Starpharma. It utilizes Starpharma's proprietary Dendrimer-Enhanced Product (DEP) platform, consisting of a generation 4 polylysine dendrimer conjugated to a HER2-targeting single-domain antibody (VHH/nanobody) and 16 deferoxamine (DFO) chelation groups radiolabeled with zirconium-89 (89Zr). Designed for positron emission tomography-computed tomography (PET-CT) imaging, DEP-HER2-DFO-89Zr exhibits rapid tumor accumulation, sustained retention, and fast clearance from vascular circulation, offering superior tumor-to-background contrast compared to traditional antibody-based radiodiagnostics like radiolabeled trastuzumab.
- Other names
- DEP-HER2 radiodiagnosticDEP-HER-2 radiodiagnosticDEP-HER 2 radiodiagnosticDEP-HER2-zirconiumDEP-HER-2-zirconiumDEP-HER 2-zirconium
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on DEP-HER2-DFO-89Zr.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEP-HER2-DFO-89Zr.